Abstract:Background: Resveratrol, a natural polyphenolic phytoalexin, has potent anti-tumor activity. Recently, it was found to induce autophagy in cancer cells. However, the effects of resveratrol on autophagy in non-small-cell lung cancer (NSCLC) cells have not yet been clearly elucidated. Materials and methods: A549 and H1299 cells were treated with different concentrations of resveratrol. Cell growth and apoptosis were measured by CCK-8 assay and flow cytometry, respectively. A549 cells were then treated with 200 μM resveratrol or SRT1720. Cell autophagy was detected by western blot and immunofluorescence. Results: In this study, we found that resveratrol exerted the anti-tumor effect through inhibiting cell proliferation and promoting cell apoptosis in NSCLC cells dose-dependently. Resveratrol has also increased the relative expression of Beclin1 and LC3 II/I while decreased p62 expression, suggesting that resveratrol induced autophagy in NSCLC cells. In addition, resveratrol increased SIRT1 expression and SIRT1 activator SRT1720-induced autophagy of NSCLC cells. SIRT1 knockdown reduced resveratrol-induced autophagy significantly. These results indicated that resveratrol might induce autophagy through upregulating SIRT1 expression. Moreover, inhibiting autophagy by autophagy inhibitor 3-methyladenine or SIRT1 inhibitor nicotinamide significantly suppressed proliferation while promoted apoptosis compared with the resveratrol 200 μM group, suggesting that resveratrol-induced autophagy might act as a protective mechanism to promote NSCLC cell survival and inhibiting autophagy can enhance the anti-tumor effect of resveratrol. Besides that, resveratrol treatment inhibited Akt/mTOR while p38-MAPK was activated in NSCLC cells in a dose-dependent manner. Activating Akt/ mTOR pathway by IGF-1 or inhibiting p-38-MAPK pathway by doramapimod significantly inhibited cell proliferation while increased cell apoptosis of NSCLC cells compared with the resveratrol 200 μM group. Conclusion: Taken together, our findings suggest that resveratrol inhibited proliferation but induced apoptosis and autophagy via inhibiting Akt/mTOR and activating p38-MAPK pathway. Resveratrol-induced autophagy might act as a protective mechanism to promote NSCLC cell survival. Therefore, inhibition of autophagy may enhance the anti-tumor activity of resveratrol in NSCLC.

Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Experimental Studies on Radiation-Inducible Human TNF Gene Therapy for Cancer

Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol

Construction of Tumor Necrosis Factor Α(tnf-Α) Expression Vector Driven by a Hypoxia/radiation Dual-Sensitive Promoter and Observation of Improved Efficacy of TNF-α Expression in A549 Cells Transfected with the Vector and Its Subcutaneous Xe

mdr1 promoter-driven tumor necrosis factor-α expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors

Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer

Therapeutic Efficacy Of An Htert Promoter-Driven Oncolytic Adenovirus That Expresses Apoptin In Gastric Carcinoma

Tumor‐necrosis Factor Can Enhance Radio‐antibody Uptake in Human Colon Carcinoma Xenografts by Increasing Vascular Permeability

The Progress of Tumor Gene-Radiotherapy Induced by Egr-1 Promoter

Complete Regression of Established Murine Hepatocellular Carcinoma by in Vivo Tumor Necrosis Factor Alpha Gene Transfer

Prolonged and Effective Blockade of Tumor-Necrosis-Factor Activity Through Adenovirus-Mediated Gene-Transfer

AAV-mediated TRAIL Gene Expression Driven by Htert Promoter Suppressed Human Hepatocellular Carcinoma Growth in Mice

Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy

Suppression of Teratocarcinoma Growth by Soluble Trail Gene Expression Driven by the Progression-Elevated Gene-3 Promoter

Preliminary Study on Conquering Multidrug Resistance with Exogenous TNF-α Gene Therapy

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK

Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts